Bli medlem
Bli medlem

Du är här

2021-10-28

REVENUE GROWTH WITH INCREASED PROFITABILITY

THIRD QUARTER 2021

  • Order intake increased 2% to 82.1 (80.5) MSEK (8% in constant currencies)
  • Order backlog amounted to 372.2 (305.8) MSEK.
  • Revenue increased 20% to 63.2 (52.6) MSEK (25% in constant currencies).
  • Operating income amounted to 8.8 (5.4) MSEK, corresponding to a margin of 13.9 (10.3) %.
  • Net results after tax amounted 4.9 (3.8) MSEK.
  • Result per share amounted to 0.15 (0.11) SEK.

JANUARY – SEPTEMBER 2021

  • Order intake increased 16% to 221.2 (190.5) MSEK (19% in constant currencies).
  • Revenue increased 25% to 183.7 (147.3) MSEK (31% in constant currencies).
  • Operating income amounted to 21.1 (7.3) MSEK, corresponding to a margin of 11.5 (4.9) %.
  • Net results after tax amounted 13.7 (1.8) MSEK.
  • Result per share amounted to 0.41 (0.06) SEK.

Comments from Tim Thurn, CEO

We are reporting yet another successful quarter, featured by a solid revenue growth of 25 percent and an operating profit margin of 14 percent. As announced separately another linac vendor, Accuray, decided to develop an interface to our surface tracking solution Catalyst+. We see this step as another confirmation of the journey towards the goal to make surface tracking standard of care in advanced radiation therapy.

Except for our customers in the APAC region the burden of the pandemic is weighing less than the need to get C-RAD’s technology implemented in the clinical workflows. Order intake for the quarter grew with 8 percent compared to last year, with variation between the regions. We saw a significant growth in the Americas market of 84 percent, driven by a well progressing cooperation with Elekta in North America, and a market in need of sophisticated patient positioning systems to adapt high precision radiation therapy. Total revenue in Americas grew 168 percent in the quarter. Whereas APAC is delivering a stable revenue, order intake declined compared to a very strong third quarter in 2020 and with current market conditions still affected by the pandemic. Despite a forward-looking approach in securing the supply chain, C-RAD was somewhat affected by late incoming components during the last quarter, resulting in delivery limitations mainly for the HIT laser products affecting the APAC region adversely. Europe showed consistent growth both in terms of order intake and revenue compared to the same period last year.

Our positioning products shows continuous notable growth - underlining the increasing demand for our technology and the customers commitment to have their solutions serviced by C-RAD. Revenue in our service business (life-cycle business) grew with 49 percent over the third quarter last year and is reflecting 14 percent of the total revenue vs 11 percent in the previous year – a very encouraging development.

Even though marketing activities such as exhibitions and face to face customer meetings have resumed in large parts of the world, it is evident that the interaction between vendor and customer has changed and is conducted in a mainly digital form. As less traveling is required, we were able to reduce related cost during the pandemic and to keep them significantly below pre-pandemic levels. We can conduct product presentations from our studio in the office, customers can engage with various C-RAD experts during the sales process through web meetings and services are increasingly performed through remote-service-systems. Digital interactions are certainly becoming the new normal which enhances our global reach.

As a result of our active work with key suppliers and a favorable sales channel and product mix, we are closing the quarter with a close to 64 percent gross margin. Growing revenue, an improved gross margin in combination with well controlled expenses allowed C-RAD to deliver an operating profit of 8.8 MSEK. Looking at nine-month period 2021, we succeeded to grow revenue with 31 percent and generated an operating profit of 21 MSEK, corresponding to a margin of 12 percent.

I am proud of what we - the C-RAD team - together with partners and customers have achieved thus far 2021. While we are still operating in a strained environment, where external factors might have a short-term impact, I am confident about C-RAD’s opportunity also moving forward. We are motivated by the customers interest in cooperating with C-RAD and are looking forward to a fourth quarter with high level of activity.

Tim Thurn, CEO

For further information:


Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com

About C-RAD


C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit http://www.c-rad.com

This information is information that C-Rad is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-10-28 08:30 CEST.

Attachments


C RAD DELÅRSRAPPORT 2021 Q3 ENG

Författare MFN